{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T13:05:40Z","timestamp":1788440740378,"version":"build-2803163510"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,6,30]],"date-time":"2017-06-30T00:00:00Z","timestamp":1498780800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1007\/s10147-017-1157-3","type":"journal-article","created":{"date-parts":[[2017,6,30]],"date-time":"2017-06-30T09:08:57Z","timestamp":1498813737000},"page":"1052-1059","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Randomized phase II study of daily and alternate-day administration of S-1 for advanced gastric cancer (JFMC43-1003)"],"prefix":"10.1007","volume":"22","author":[{"given":"Hiroaki","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuro","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masataka","family":"Taguri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuo","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Muguruma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Koeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masazumi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikihito","family":"Nakamori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Konno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihito","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Hosoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuhiko","family":"Shirasaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susumu","family":"Yamamitsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michio","family":"Sowa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Kitajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masazumi","family":"Okajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiya","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigetoyo","family":"Saji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosei","family":"Hirakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,30]]},"reference":[{"issue":"12","key":"1157_CR1","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1002\/ijc.25516","volume":"127","author":"J Ferlay","year":"2010","unstructured":"Ferlay J, Shin HR, Bray F et al (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127(12):2893\u20132917. doi:\n                        10.1002\/ijc.25516","journal-title":"Int J Cancer"},{"issue":"3","key":"1157_CR2","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1159\/000012032","volume":"57","author":"K Sugimachi","year":"1999","unstructured":"Sugimachi K, Maehara Y, Horikoshi N et al (1999) An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. The S-1 Gastrointestinal Cancer Study Group. Oncology 57(3):202\u2013210","journal-title":"Oncology"},{"issue":"5","key":"1157_CR3","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/00001813-199607000-00010","volume":"7","author":"T Shirasaka","year":"1996","unstructured":"Shirasaka T, Shimamato Y, Ohshimo H et al (1996) Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7(5):548\u2013557","journal-title":"Anticancer Drugs"},{"issue":"3","key":"1157_CR4","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1159\/000012099","volume":"58","author":"W Koizumi","year":"2000","unstructured":"Koizumi W, Kurihara M, Nakano S et al (2000) Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology 58(3):191\u2013197","journal-title":"Oncology"},{"issue":"11","key":"1157_CR5","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/S0959-8049(98)00211-1","volume":"34","author":"Y Sakata","year":"1998","unstructured":"Sakata Y, Ohtsu A, Horikoshi N et al (1998) Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1M tegafur-0.4\u00a0M gimestat-1M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 34(11):1715\u20131720","journal-title":"Eur J Cancer"},{"issue":"11","key":"1157_CR6","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/S1470-2045(09)70259-1","volume":"10","author":"N Boku","year":"2009","unstructured":"Boku N, Yamamoto S, Fukuda H et al (2009) Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol 10(11):1063\u20131069. doi:\n                        10.1016\/S1470-2045(09)70259-1","journal-title":"Lancet Oncol"},{"issue":"3","key":"1157_CR7","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S1470-2045(08)70035-4","volume":"9","author":"W Koizumi","year":"2008","unstructured":"Koizumi W, Narahara H, Hara T et al (2008) S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9(3):215\u2013221. doi:\n                        10.1016\/S1470-2045(08)70035-4","journal-title":"Lancet Oncol"},{"issue":"86\u201387","key":"1157_CR8","first-page":"1939","volume":"55","author":"E Ako","year":"2008","unstructured":"Ako E, Ohira M, Yamashita Y et al (2008) Efficacy of S-1 for gastric cancer patients with positive peritoneal lavage cytology. Hepatogastroenterology 55(86\u201387):1939\u20131942","journal-title":"Hepatogastroenterology"},{"key":"1157_CR9","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1186\/s12885-015-1476-6","volume":"15","author":"C Matsuda","year":"2015","unstructured":"Matsuda C, Uemura M, Nakata K et al (2015) Randomized phase II study of S-1 dosing schedule for resected colorectal cancer. BMC Cancer 15:452. doi:\n                        10.1186\/s12885-015-1476-6","journal-title":"BMC Cancer"},{"issue":"1","key":"1157_CR10","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00280-013-2323-6","volume":"73","author":"H Yamaue","year":"2014","unstructured":"Yamaue H, Satoi S, Kanbe T et al (2014) Phase II clinical study of alternate-day oral therapy with S-1 as first-line chemotherapy for locally advanced and metastatic pancreatic cancer. Cancer Chemother Pharmacol 73(1):97\u2013102. doi:\n                        10.1007\/s00280-013-2323-6","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"1157_CR11","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s10147-004-0381-9","volume":"9","author":"W Arai","year":"2004","unstructured":"Arai W, Hosoya Y, Hyodo M et al (2004) Alternate-day oral therapy with TS-1 for advanced gastric cancer. Int J Clin Oncol 9(3):143\u2013148. doi:\n                        10.1007\/s10147-004-0381-9","journal-title":"Int J Clin Oncol"},{"issue":"17","key":"1157_CR12","first-page":"4004","volume":"53","author":"T Shirasaka","year":"1993","unstructured":"Shirasaka T, Shimamoto Y, Fukushima M (1993) Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Can Res 53(17):4004\u20134009","journal-title":"Can Res"},{"issue":"6","key":"1157_CR13","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s10147-008-0780-4","volume":"13","author":"W Arai","year":"2008","unstructured":"Arai W, Hosoya Y, Haruta H et al (2008) Comparison of alternate-day versus consecutive-day treatment with S-1: assessment of tumor growth inhibition and toxicity reduction in gastric cancer cell lines in vitro and in vivo. Int J Clin Oncol 13(6):515\u2013520. doi:\n                        10.1007\/s10147-008-0780-4","journal-title":"Int J Clin Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-017-1157-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-017-1157-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-017-1157-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,11,7]],"date-time":"2017-11-07T12:09:06Z","timestamp":1510056546000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-017-1157-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,30]]},"references-count":13,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["1157"],"URL":"https:\/\/doi.org\/10.1007\/s10147-017-1157-3","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,30]]}}}